

Table S1 Detailed information on neoadjuvant treatment.

| Variables | N (%) |
|------------------------------|--------------|
| Types of regimens | |
| FOLFIRINOX | 91 (89.2) |
| Gemcitabin-nab-paclitaxel | 9 (8.8) |
| CCRT | 2 (2.0) |
| Cycle, median (IQR) | 6 (4-10) |
| RECIST response | |
| Complete Response | 1 (0.9) |
| Partial Response | 30 (27.3) |
| Stable Disease | 72 (65.5) |
| Progressive Disease | 7 (6.4) |
| CA19-9 response [†] | |
| Yes | 52 (47.3) |
| No | 33 (30.0) |
| Initially not elevated | 25 (22.7) |
| Conversion Surgery | |
| Curative-intent Surgery | 62 (56.3) |

[†]Response was defined if the value measured after 4 cycles of chemotherapy was decreased by more than 50% from the initial.